U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

Mydecine has announced that the U.S. Food and Drug Administration has cleared MYCO-001 in a recent Investigational New Drug (IND) application, marking the first clearance of the company’s drug product.

Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

📰 Weekly newsletter about the psychedelic research

✔️ Unlimited access to our database and original articles

🖊️ Add (private) notes and comments to each page

Make an account
Category Press Release
Published in Bloomberg

Companies Featured

Mydecine (Mydecine Innovations Group Inc.) is the parent organization of Mindleap, Mydecine Health Sciences, and NeuroPharm.

Inline Feedbacks
View all comments